Cited by 153BRCA gene mutations in cancerBreast Implant and ReconstructionWomen's cancer prevention and management

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic

Open access

Heemskerk-Gerritsen, Bernadette A. M., Brekelmans, Cecile T. M., Menke-Pluymers, Marian B. E., van Geel, Albert N., Tilanus-Linthorst, Madeleine M. A., Bartels, Carina C. M., Tan, Murly, Meijers-Heijboer, Hanne E. J., Klijn, Jan G. M., Seynaeve, Caroline·2007·Annals of Surgical Oncology

DOI 10.1245/s10434-007-9449-xPMC PMC2077910

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: BRCA1/2 mutation carriers and women from a hereditary breast(/ovarian) cancer family have a highly increased risk of developing breast cancer (BC). Prophylactic mastectomy (PM) results in the greatest BC risk reduction. Long-term data on the efficacy and sequels of PM are scarce. METHODS: From 358 high-risk women (including 236 BRCA1/2 carriers) undergoing PM between 1994 and 2004, relevant data on the occurrence of BC in relation to PM, complications in relation to breast reconstruction (BR), mutation status, age at PM and preoperative imaging examination results were extracted from the medical records, and analyzed separately for women without (unaffected, n = 177) and with a BC history (affected, n = 181). RESULTS: No primary BCs occurred after PM (median follow-up 4.5 years). In one previously unaffected woman, metastatic BC was detected almost 4 years after PM (primary BC not found). Median age at PM was younger in unaffected women (P < .001), affected women more frequently were 50% risk carriers (P < .001). Unexpected (pre)malignant changes at PM were found in 3% of the patients (in 5 affected, and 5 unaffected women, respectively). In 49.6% of the women opting for BR one or more complications were registered, totaling 215 complications, leading to 153 surgical interventions (71%). Complications were mainly related to cosmetic outcome (36%) and capsular formation (24%). CONCLUSIONS: The risk of developing a primary BC after PM remains low after longer follow-up. Preoperative imaging and careful histological examination is warranted because of potential unexpected (pre)malignant findings. The high complication rate after breast reconstruction mainly concerns cosmetic issues.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1245/s10434-007-9449-x

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766 · cited 5×
“09 Necrosis 11 (26) 4 (13) Bleeding 20 (48) 12 (39) Prosthesis luxation 2 (5) 0 (0) Poor arterial inflow 0 (0) 1 (3) Pneumothorax 1 (2) 0 (0) Late complications Surgery due to late complication No 11 (13) 7 (12) .”
Influential
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399 · cited 4×
“001 Death due to cancer 0 (0) 1 (3) 9 (10) 7 (8) Age at PM (years) Median 36.”
Influential
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229 · cited 4×
“33 Necrosis 1 (1) 3 (5) Capsular formation 31 (37) 20 (35) Prosthesis luxation 2 (2) 3 (5) Poor cosmetic appearance d 31 (37) 19 (34) Dog ear 16 (19) 12 (21)”
Influential
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H. L., Tilanus‐Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,686 · cited 2×
“74 Late (>6 weeks after BR) 85 (67) 57 (65) Surgery due to late complication No 38 (30) 24 (27) .”
Self-citation
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,428 · cited 2×
“001 Death due to cancer 0 (0) 1 (3) 9 (10) 7 (8) Age at PM (years) Median 36.”
Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171 · cited 2×
“11 At PM 35 (42) 1 (33) 16 (26) 5 (42) After PM 30 (36) 0 (0) 31 (51) 1 (8) Ovarian cancer before PM 4 (3) 0 (0) 2 (2) 1 (1) Unexpected (p)MF at PM 3 (2) 2 (6) 4 (4) 1 (1) Cancer after PM Breast cancer 1 (1) 0 (0) 0 (0) 0 (0) Ovarian cancer 2 (1) 0 (0) 1 (1) 0 (0)”
Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer
Kuhl, C. K., Schrading, S., Leutner, C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W. C., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,148 · cited 2×
“001 30–39 years 88 (50) 48 (27) 40–49 years 46 (26) 69 (38) ‡50 years 22 (12) 56 (31) PBSO Yes 86 (49) 73 (40) .”
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973 · cited 3×
“33 Necrosis 1 (1) 3 (5) Capsular formation 31 (37) 20 (35) Prosthesis luxation 2 (2) 3 (5) Poor cosmetic appearance d 31 (37) 19 (34) Dog ear 16 (19) 12 (21)”
Self-citation
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743 · cited 1×
“001 Range 22–65 28–55 25–65 26–68 <30 years 18 (12) 3 (9) 6 (7) 2 (2) <.”

Show all 38 references

Sorted by citations

Items 101–152 of 152

Prise en charge du cancer du sein infiltrant de la femme non ménopausée
(2009) · ONCOLOGIE · doi:10.1007/s10269-009-1818-6 · Cited by 3
Alterations in the preneoplastic breast microenvironment of BRCA1/2 mutation carriers revealed by spatial transcriptomicsPreprint
Caputo, A., Vipparthi, K., Bazeley, P., Downs-Kelly, E., McIntire, P., Ni, Y., Hu, B., Keri, R., & Karaayvaz, M. (2023) · bioRxiv · doi:10.1101/2023.05.24.542078 · Cited by 4
“There are currently few chemoprevention strategies available for BRCA1/2 mutation carriers, 83 and irreversible prophylactic mastectomy is the primary option [4].”
Germline Pathogenic Variant Prediction Model for Tumor-Only Sequencing Based on Japanese Clinicogenomic Database
Ikegami, M., Zhang, L., Hirata, M., Yamaguchi, T., Oda, S., Kohsaka, S., Mano, H., Hirai, T., & Kobayashi, H. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2985 · Cited by 2
La prise en charge des risques familiaux sans mutation
Mouret‐Fourme, E., & Noguès, C. (2014) · ONCOLOGIE · doi:10.1007/s10269-014-2449-4 · Cited by 2
Breast cancer inBRCAmutation carriers: breast-conserving therapy or bilateral mastectomy?
Murphy, J. O., & Sacchini, V. (2013) · Clinical Practice · doi:10.2217/cpr.13.72 · Cited by 2
Complications of Prosthetic Breast Reconstruction in Prophylactic Versus Therapeutic Mastectomy: A Systematic Review and Meta-analysis
Schelletter, M., Dong, E. T. C., Tekdogan, B., & Oranges, C. M. (2025) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000006904 · Cited by 1
“17–24 This process should incorporate evidence to weigh risks, benefits, and patient preferences.”
Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada
Mashal, S., Melanson, A., Apostolova, C., Ferroum, A., Villareal-Corpuz, V., Meterissian, S. H., Martel, K., Boileau, J.-F., Basik, M., Foulkes, W. D., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19375-w · Cited by 1
Uptake of risk-reducing medical interventions among female BRCA1/2 pathogenic variant carriers: A population-based study in British Columbia
Lloyd-Ellis, S., Kaur, P., Kwon, J. S., Dawson, L., & Hanley, G. E. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.05.018 · Cited by 1
Poly(ADP-Ribose) Inhibition: Exploring a New Approach to Breast Cancer Prevention in BRCA1/2 Mutation Carriers
Smith, K. L., & Isaacs, C. J. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0049-1 · Cited by 1
Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers
Maxwell, K. N., & Domchek, S. M. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0086-4 · Cited by 1
“The presence of premalignant or malignant lesions in the breasts of BRCA1/2 carriers at the time of RRM provides support for the use of the procedure, and it was suggested that such lesions are more common in BRCA1/2 carriers [23, 25, 26].”
Background
Strategies for Risk Reduction
Voltura, A., & Jacobs, L. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4932-6.50011-1 · Cited by 1
Ductal invasive carcinoma arising within atypical microglandular adenosis in a patient with BRCA-1 mutation: A case report
Ricci, C., Serra, M., Locatelli, F., Laudo, M. D., Zuntini, R., Santini, D., Taffurelli, M., & Turchetti, D. (2017) · Human Pathology Case Reports · doi:10.1016/j.ehpc.2016.10.008 · Cited by 1
Management of Hereditary Breast Cancer: An Overview
Kattepur, A. K., & Gopinath, K. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-4546-4_18 · Cited by 1
BRCA1 and BRCA2 Testing in Inherited Breast Cancer
Bowles, K. R., & Rosenthal, E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8127-0_10 · Cited by 1
Surgical Options for Primary Prevention: Prophylactic Mastectomy and Oophorectomy
Murphy, J. O., & Sacchini, V. (2020) · Springer eBooks · doi:10.1007/978-3-030-41207-4_18 · Cited by 1
Present Options in the Prevention of Breast Cancer
Russo, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-72815-1_7 · Cited by 1
Psychological impact of genetic testing for Lynch syndrome in new patients with colorectal cancer and educational-support groups for female BRCA-mutation carriers
Landsbergen, K. M. (2011) · Radboud Repository (Radboud University)
BRCA1- und BRCA2-Genmutationen: Klinische Konsequenzen beim vererbbaren Brust- und Eierstockkrebs
Pristauz, G., Geigl, J. B., & Petru, E. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0772-7
Identification and Management of Women at High Familial Risk for Breast Cancer
Kurian, A. W., & Ford, J. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6076-4_13
Risk Reduction Strategies: Surgical Perspective
Spiguel, L. R., & Hansen, N. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5891-3_8
Bioethics and Medicolegal Aspects in Breast Cancer Reconstruction
Urban, C. D. A., Rabinovich, Í., Hurley, J., & Rietjens, M. (2013) · Springer eBooks · doi:10.1007/978-88-470-2652-0_49
Risk-Reducing Mastectomy: Who Is a Candidate and What Are the Outcomes?
Newman, L. A. (2013) · Current Breast Cancer Reports · doi:10.1007/s12609-013-0110-3
Surgical Management of Inherited Susceptibility to Breast Cancer
Freisinger, F., & Domchek, S. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-87583-5_4
Editorial: More Answers About Prophylactic Mastectomy
Wood, W. C. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9507-4
“Heemskerk-Gerritsen et al.(1) continue to add to our understanding of the surgical management of hereditary breast and ovarian cancer.”
Background
Contralateral mastectomy in patients treated for unilateral breast cancer
McGuire, K. P., Lee, M. C., & Laronga, C. (2009) · Current Breast Cancer Reports · doi:10.1007/s12609-009-0015-3
BILATERAL PROPHYLACTIC MASTECTOMY AND IMMEDIATE BREAST RECONSTRUCTION WITH IMPLANTS
Gahm, J. (2009) · Figshare
The Psychosocial Impact of Prophylactic Mastectomy and Salpingo-Oophorectomy
Bresser, P. J. C. (2009) · RePub (Erasmus University Rotterdam)
À propos d'une série rétrospective de cancers du sein diagnostiqués auprès de patientes présentant une mutation constitutionnelle des gènes BRCA1 ou BRCA2: traitement et suivi à long terme
Artiguenave, M. (2015) · HAL
Prophylactic Mastectomy after Planned Submuscular Breast Augmentation
Sreetharan, V., van der Lei, B., de Vries, J., & Wermter, T. B. (2014) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000437241.38424.bb
Breast conservation surgery and radiation for a patient with synchronous primary breast cancers and BRCA1/BRCA2 positivity: is mastectomy required?
Trombetta, M. G., Kotinsley, K., & Julian, T. B. (2011) · Journal of Radiotherapy in Practice · doi:10.1017/s1460396911000021
“Local therapy has traditionally involved ipsilateral therapeutic mastectomy and contralateral prophylactic mastectomy.(1,2) The physical and emotional body self image distress associated with mastectomy has been well described.”
Background
Which Surgery in Geriatric Breast Cancer
Graziano, P. (2016) · Journal of Surgery and Surgical Research · doi:10.17352/2455-2968.000023
“In stages III and IV, in the presence of ASA *( is a high removal was performed (lumpectomy) under regional anesthesia with sedation, as proposed by several authors [14] and in day surgery [15,16].”
Background
Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer
Tran, G., Helm, M., & Litton, J. K. (2016) · Current Breast Cancer Reports · doi:10.1007/s12609-016-0220-9
La prise en charge des risques familiaux sans mutation The Management of Non-Mutated Family Risks
Sas, L. (2014)
Hereditary Breast Cancer
y Cajal, T. R., Manrique, A. C. V., & Dueñas, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-56673-3_41
Screening for High-Familial-Risk Women
Vourtsis, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56673-3_6
Risk and Prevention for Highly Penetrant Genes
Chitalia, A., Khoury, K. E., & Isaacs, C. J. (2018) · Current Breast Cancer Reports · doi:10.1007/s12609-018-0282-y
“number of studies have evaluated the role of RRM including a prospective study of 358 high-risk women (including 236 BRCA1/2 mutation carriers) who had undergone RRM [19].”
Background
Hereditary Breast Cancer: Prophylactic Mastectomy, Breast Conservation, and Rates of Cancer
Walsh, S. M., Robson, M. E., & Sacchini, V. (2019) · Springer eBooks · doi:10.1007/978-3-319-62927-8_4
Lifestyle Changes and Prevention: Unique Issues for Young Women
LeVasseur, N., Yerushalmi, R., & Gelmon, K. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-24762-1_16
A reproductive dilemma?
Giacomina, G.-H. J. J. (2020) · doi:10.26481/dis.20201210jg
Genetic Predispositions and Prophylactic Mastectomy in Breast Cancer Patients
Soran, A., & Şenol, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-66853-2_7
Breast Cancer Risk-reducing Strategies in BRCA1/2 Mutation Carriers
Heemskerk‐Gerritsen, B. A. M. (2014) · EUR Research Repository (Erasmus University Rotterdam)
Self-citation
Current World Literature
(2009) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3283240745
Bioethics and Medicolegal Aspects in Breast Cancer Reconstruction
Urban, C. D. A., Rabinovich, Í., Hurley, J., Rietjens, M., & Anselmi, K. F. (2019) · Springer eBooks · doi:10.1007/978-3-319-62927-8_73
Quality of Life is Essential: Implications for Diagnosis and Treatment for BRCA1/2 Germline Mutations
Sánchez-Contreras, Y., Poveda, B. I. A., Gutierrez, D. N. A., & Gómez, R. M. Á. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106666
Breast cancer referrals to NHS Tayside genetic service: Are we meeting target timelines?
Swan, R. E., Pitcathley, M., Dunlop, J., & Choong, W. L. (2023) · Breast Global Journal · doi:10.4103/bgj.bgj_19_23
Secondary Risk-Reducing Strategies for Contralateral Breast Cancer in BRCA1/2 Variant Carriers: A Systematic Review and Meta-analysis
Yu, J., Jiang, S., Liu, T., Gao, Y., Ma, X., Fekadu, G., Xia, Y., Parkinson, B., Ming, W., & Gu, Y. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03054-x
“Research has demonstrated that CRRM can decrease the likelihood of CBC by as much as 95% [15], rendering it a highly efficacious yet significantly invasive alternative.”
Paravertebral Blocks in Implant-Based Breast Reconstruction Do Not Induce Increased Postoperative Blood or Drainage Fluid Loss
Flores, T., Jaklin, F. J., Mayrl, M. S., Kerschbaumer, C., Glisic, C., Pfoser, K., Lumenta, D. B., Schrögendorfer, K. F., Hörmann, C., & Bergmeister, K. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061832
Additional file 3 of Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"
Deutschmann, C., Singer, C. F., Gschwantler-Kaulich, D., Pfeiler, G., Leser, C., Baltzer, P., Helbich, T. H., Kraus, C., Korbatits, R., Marzogi, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619492
Additional file 4 of Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"
Deutschmann, C., Singer, C. F., Gschwantler-Kaulich, D., Pfeiler, G., Leser, C., Baltzer, P., Helbich, T. H., Kraus, C., Korbatits, R., Marzogi, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619495
Additional file 2 of Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"
Deutschmann, C., Singer, C. F., Gschwantler-Kaulich, D., Pfeiler, G., Leser, C., Baltzer, P., Helbich, T. H., Kraus, C., Korbatits, R., Marzogi, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619489
Additional file 1 of Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"
Deutschmann, C., Singer, C. F., Gschwantler-Kaulich, D., Pfeiler, G., Leser, C., Baltzer, P., Helbich, T. H., Kraus, C., Korbatits, R., Marzogi, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619486
Design and Synthesis of Novel 1,2,3-Triazole Derivatives as Non-Steroidal Aromatase Inhibitors for Estrogen-Responsive Breast Cancer
Mansour, A., Hassan, L., & Saeed, O. (2023) · Pharmaceutical Sciences and Drug Design · doi:10.51847/flor0ckeu2

Authors: Heemskerk-Gerritsen, B. A. M., Brekelmans, C. T. M., Menke-Pluymers, M. B. E., van Geel, A. N., Tilanus-Linthorst, M. M. A., Bartels, C. C. M., Tan, M., Meijers-Heijboer, H. E. J., Klijn, J. G. M., & Seynaeve, C.
Affiliations: Erasmus MC Cancer Institute (NL)
Corresponding author: Seynaeve, Caroline
ORCID: Meijers-Heijboer, Hanne E. J.
Venue: Annals of Surgical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2007-05-31
Volume: 14
Issue: 12
Pages: 3335-3344
ISSN: 1068-9265 (ISSN-L)
1534-4681
DOI: 10.1245/s10434-007-9449-x
PMC: PMC2077910
OpenAlex: W2108830626
Cited by: 153
References: 38
Citations by year: 2026: 3 · 2025: 3 · 2024: 4 · 2023: 10 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 7 · 2017: 7 · 2016: 11 · 2015: 9 · 2014: 14 · 2013: 14 · 2012: 6
FWCI: 5.89
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
Locations: Annals of Surgical Oncology (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Surgery › Breast Implant and Reconstruction
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Keywords: prophylactic mastectomy, BRCA1 mutation carriers, BRCA2 mutation carriers, hereditary breast cancer, breast reconstruction complications, capsular contracture, cosmetic outcome, preoperative imaging, breast cancer risk reduction, high-risk women
MeSH terms: Adult, Breast Neoplasms, Female, Follow-Up Studies, Humans, Longitudinal Studies, Mastectomy, Middle Aged, Mutation, Neoplasm Staging, Netherlands, Ovarian Neoplasms, Postoperative Complications, Prospective Studies, Retrospective Studies, Risk Factors, Cohort Studies, Incidence, Mammaplasty, Treatment Outcome, Germ-Line Mutation, BRCA1 Protein, Genetic Predisposition to Disease, BRCA2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks